Candidate patients must meet the following criteria:
- Diagnosis of locally advanced pancreatic cancer
- Not a candidate for surgery
- No prior therapy for pancreatic cancer OR no more than 3 treatments with gemcitabine-Abraxane
NOTE: There may be other checks to complete before a patient can join the study. The doctor will discuss these with the patient to determine whether the patient is a good candidate for this study.
Learn more about the risk factors and early warning signs of pancreatic cancer, the importance of clinical trials for Stage III Locally Advanced Pancreatic Cancer patients and more about the TIGeR-PaC clinical trial at pancreatic-clinical-trials.info.